Liver Injury during Highly Active Antiretroviral Therapy: The Effect of Hepatitis C Coinfection

Clinical Infectious Diseases

Volumn 38, Issue SUPPL. 2, 2004, Pages

  Bonacini, Maurizio ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; BILIRUBIN; CORE PROTEIN; GLUTATHIONE; LIVER ENZYME; RECOMBINANT INTERFERON; RIBAVIRIN; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; DRUG MONITORING; ENZYME ANALYSIS; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IMMUNOPATHOGENESIS; IMMUNOPROPHYLAXIS; LIVER FUNCTION TEST; LIVER TOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; ARTICLE; CHEMICALLY INDUCED DISORDER; ENZYMOLOGY; HEPATITIS C VIRUS; LIVER DISEASE; RISK FACTOR;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER DISEASES; RISK FACTORS;

EID: 1542297624     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381453     Document Type: Conference Paper

References (31)

1. Sulkowski M, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 284:74-80.
2. Lewis JD, Strom BL. Balancing safety of dietary supplements with the free market. Ann Intern Med 2002; 136:616-8.
3. Wit FWNM, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
4. Zimmermann HJ. The spectrum of hepatotoxicity. In: Zimmermann HJ, ed. Hepatotoxicity. 2nd ed. Baltimore, MD: Lippincott, Williams and Wilkins, 1999.
5. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138:197-207.
6. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med 2000; 160:3365-73.
7. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Resp Crit Care Med 1998; 157:1871-6.
8. Bonacini M, Louie S, Weisman K. Hepatotoxicity of antiviral medications. In: Kaplowitz N, DeLeve L, eds. Drug-induced liver disease. New York: Marcel Dekker, 2002:519-48.
9. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
10. Bonacini M, Louie, Bzowej N. Liver mortality in patients with HIV infection [abstract]. Hepatology 2002; 36:230A.
11. Sulkowski M, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with the antiretroviral therapy containing protease inhibitors with or without pharmacokinetic boosting by low-dose ritonavir [abstract]. Hepatology 2003; 38:698A.
12. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine cohort, France, 1996-1998. AIDS 1999; 13:F115-21.
13. Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J Acquir Immune Defic Syndr 2000; 23:236-45.
14. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine containing antiretroviral therapy. AIDS 2001; 15:1261-8.
15. Monforte AA, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28: 114-23.
16. Aceti A, Pasquazzi C, Zechini B, De Bac C, LIVERHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29:41-8.
17. Puoti M, Torti C, Ripamonti D, the HIV-HCV Co-Infection Study Group. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32:259-67.
18. Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis 2004; 38:S49-55 (in this issue).
19. Martin-Carbonero L, Nunez M, Rios P, Perez-Olmeda M, Soriano V. Liver injury after beginning antiretroviral therapy in HIV/HCV coinfected patients is not associated to immune reconstitution. AIDS 2002; 16:1423-5.
20. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in HCV RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects. AIDS 2002; 16: 1915-23.
21. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:F25-32.
22. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-20.
23. Ogedegbe AE, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 2003; 3:329-37.
24. Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C-associated hepatocarcinogenesis. Cancer Res 2001; 61:4365-70.
25. De Rosa SC, Zaretsky MD, Dubs JG, et al. N-acetylcysteine replenished glutathione in HIV infection. Eur J Clin Invest 2000; 30:915-29.
26. Barbaro G. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings et al. Am J Gastroenterol 1999; 94:2198-205.
27. Lai MMC. Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology 2002; 122: 568-71.
28. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and HCV chronic infection in HIV-HCV coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:245-50.
29. McGovern B, Bica I. Risk of HAART therapy in hepatitis C [letter]. Hepatology 2002; 35:730.
30. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16:290-91.
31. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly-active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001; 161:1962-8.